annual cash & cash equivalents:
$5.49B-$352.00M(-6.03%)Summary
- As of today (August 31, 2025), AZN annual cash & cash equivalents is $5.49 billion, with the most recent change of -$352.00 million (-6.03%) on December 31, 2024.
- During the last 3 years, AZN annual cash & cash equivalents has fallen by -$841.00 million (-13.29%).
- AZN annual cash & cash equivalents is now -48.70% below its all-time high of $10.70 billion, reached on December 31, 2010.
Performance
AZN Cash and cash equivalents Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
Range
Earnings dates
quarterly cash & cash equivalents:
$7.11B+$1.71B(+31.75%)Summary
- As of today (August 31, 2025), AZN quarterly cash & cash equivalents is $7.11 billion, with the most recent change of +$1.71 billion (+31.75%) on June 30, 2025.
- Over the past year, AZN quarterly cash & cash equivalents has increased by +$32.00 million (+0.45%).
- AZN quarterly cash & cash equivalents is now -54.52% below its all-time high of $15.63 billion, reached on June 30, 2021.
Performance
AZN quarterly cash & cash equivalents Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
Range
Earnings dates
Cash and cash equivalents Formula
Cash & Cash Equivalents = Cash + Short-Term Investments
AZN Cash and cash equivalents Trends
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly |
|---|---|---|
| 1 y1 year | -6.0% | +0.5% |
| 3 y3 years | -13.3% | +45.5% |
| 5 y5 years | +2.2% | +16.2% |
AZN Cash and cash equivalents Highs & Lows
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | |
|---|---|---|---|---|---|
| 3 y | 3-year | -13.3% | at low | -11.4% | +45.5% |
| 5 y | 5-year | -29.9% | +2.2% | -54.5% | +45.5% |
| alltime | all time | -48.7% | +4146.4% | -54.5% | >+9999.0% |
AZN Cash and cash equivalents History
| Date | Annual | Quarterly |
|---|---|---|
| Jun 2025 | - | $7.11B(+31.8%) |
| Mar 2025 | - | $5.39B(-4.6%) |
| Dec 2024 | $5.49B(-6.0%) | $5.65B(+14.7%) |
| Sep 2024 | - | $4.93B(-30.3%) |
| Jun 2024 | - | $7.08B(-11.8%) |
| Mar 2024 | - | $8.02B(+34.5%) |
| Dec 2023 | $5.84B(-5.3%) | $5.96B(+16.6%) |
| Sep 2023 | - | $5.12B(-12.0%) |
| Jun 2023 | - | $5.81B(-10.1%) |
| Mar 2023 | - | $6.46B(+0.9%) |
| Dec 2022 | $6.17B(-2.6%) | $6.41B(+30.8%) |
| Sep 2022 | - | $4.90B(+0.2%) |
| Jun 2022 | - | $4.89B(-16.1%) |
| Mar 2022 | - | $5.82B(-9.0%) |
| Dec 2021 | $6.33B(-19.2%) | $6.40B(-10.5%) |
| Sep 2021 | - | $7.15B(-54.3%) |
| Jun 2021 | - | $15.63B(+101.3%) |
| Mar 2021 | - | $7.76B(-2.8%) |
| Dec 2020 | $7.83B(+45.9%) | $7.99B(-5.4%) |
| Sep 2020 | - | $8.45B(+38.1%) |
| Jun 2020 | - | $6.12B(+46.8%) |
| Mar 2020 | - | $4.17B(-33.0%) |
| Dec 2019 | $5.37B(+13.1%) | $6.22B(+30.1%) |
| Sep 2019 | - | $4.78B(-23.5%) |
| Jun 2019 | - | $6.25B(+26.0%) |
| Mar 2019 | - | $4.96B(-12.7%) |
| Dec 2018 | $4.75B(+42.7%) | $5.68B(+33.3%) |
| Sep 2018 | - | $4.26B(+11.9%) |
| Jun 2018 | - | $3.81B(-1.6%) |
| Mar 2018 | - | $3.87B(-15.5%) |
| Dec 2017 | $3.32B(-32.5%) | $4.58B(-12.1%) |
| Sep 2017 | - | $5.21B(-16.8%) |
| Jun 2017 | - | $6.26B(+70.6%) |
| Mar 2017 | - | $3.67B(-38.1%) |
| Dec 2016 | $4.93B(-19.6%) | $5.93B(+47.3%) |
| Sep 2016 | - | $4.03B(-13.5%) |
| Jun 2016 | - | $4.65B(+13.2%) |
| Mar 2016 | - | $4.11B(-40.1%) |
| Dec 2015 | $6.13B(-1.9%) | $6.86B(+48.8%) |
| Sep 2015 | - | $4.61B(+1.3%) |
| Jun 2015 | - | $4.55B(+22.2%) |
| Mar 2015 | - | $3.72B(-48.1%) |
| Dec 2014 | $6.25B(-31.3%) | $7.18B(+20.5%) |
| Sep 2014 | - | $5.96B(+3.1%) |
| Jun 2014 | - | $5.78B(+11.9%) |
| Mar 2014 | - | $5.16B(-48.6%) |
| Dec 2013 | $9.10B(+22.9%) | $10.05B(+20.5%) |
| Sep 2013 | - | $8.34B(-8.3%) |
| Jun 2013 | - | $9.10B(+13.3%) |
| Mar 2013 | - | $8.03B(-6.1%) |
| Dec 2012 | $7.40B | $8.55B(+25.5%) |
| Sep 2012 | - | $6.82B(-25.9%) |
| Date | Annual | Quarterly |
|---|---|---|
| Jun 2012 | - | $9.20B(-8.0%) |
| Mar 2012 | - | $10.00B(-7.5%) |
| Dec 2011 | $7.03B(-34.3%) | - |
| Sep 2011 | - | $10.81B(+5.0%) |
| Jun 2011 | - | $10.30B(-4.6%) |
| Mar 2011 | - | $10.79B(-6.8%) |
| Dec 2010 | $10.70B(+7.9%) | - |
| Sep 2010 | - | $11.58B(+4.7%) |
| Jun 2010 | - | $11.05B(+17.6%) |
| Mar 2010 | - | $9.40B(+29.2%) |
| Dec 2009 | $9.92B(+131.4%) | - |
| Jun 2009 | - | $7.27B(+60.7%) |
| Mar 2009 | - | $4.52B(+24.7%) |
| Dec 2008 | $4.29B(-26.9%) | - |
| Sep 2008 | - | $3.63B(-19.5%) |
| Jun 2008 | - | $4.51B(+38.5%) |
| Mar 2008 | - | $3.26B(-54.1%) |
| Dec 2007 | $5.87B(-17.4%) | - |
| Dec 2006 | $7.10B(+42.7%) | - |
| Jun 2006 | - | $7.10B(+17.4%) |
| Mar 2006 | - | $6.05B(+6.9%) |
| Dec 2005 | $4.98B(+371.9%) | - |
| Sep 2005 | - | $5.66B(-3.3%) |
| Jun 2005 | - | $5.85B(+20.3%) |
| Mar 2005 | - | $4.86B(+16.0%) |
| Dec 2004 | $1.05B(+43.9%) | - |
| Sep 2004 | - | $4.19B(+3.2%) |
| Jun 2004 | - | $4.06B(-2.9%) |
| Mar 2004 | - | $4.18B(-2.4%) |
| Dec 2003 | $733.00M(+1.0%) | - |
| Sep 2003 | - | $4.29B(+7.8%) |
| Jun 2003 | - | $3.97B(-5.6%) |
| Dec 2002 | $726.00M(+3.0%) | - |
| Dec 2001 | $705.00M(-31.0%) | - |
| Jun 2001 | - | $4.21B(+42.9%) |
| Dec 2000 | $1.02B(+138.1%) | - |
| Jun 2000 | - | $2.95B(>+9900.0%) |
| Mar 2000 | - | $0.00(-100.0%) |
| Dec 1999 | $429.00M(-86.3%) | $429.00M(-88.7%) |
| Sep 1999 | - | $3.79B(+88.1%) |
| Jun 1999 | - | $2.02B(-35.8%) |
| Dec 1998 | $3.14B(+526.5%) | $3.14B(+859.6%) |
| Jun 1998 | - | $327.00M(-34.7%) |
| Dec 1997 | $500.89M(+12.9%) | $500.89M(+12.9%) |
| Dec 1996 | $443.54M(+76.1%) | $443.54M(+76.1%) |
| Dec 1995 | $251.87M(-70.6%) | $251.87M(-73.8%) |
| Jun 1995 | - | $961.50M(+12.2%) |
| Dec 1994 | $856.75M(-36.6%) | $856.75M(-36.6%) |
| Dec 1993 | $1.35B(+190.4%) | $1.35B |
| Dec 1992 | $465.62M(-1.6%) | - |
| Dec 1991 | $473.41M(+266.3%) | - |
| Dec 1990 | $129.24M | - |
FAQ
- What is AstraZeneca PLC annual cash & cash equivalents?
- What is the all time high annual cash & cash equivalents for AstraZeneca PLC?
- What is AstraZeneca PLC annual cash & cash equivalents year-on-year change?
- What is AstraZeneca PLC quarterly cash & cash equivalents?
- What is the all time high quarterly cash & cash equivalents for AstraZeneca PLC?
- What is AstraZeneca PLC quarterly cash & cash equivalents year-on-year change?
What is AstraZeneca PLC annual cash & cash equivalents?
The current annual cash & cash equivalents of AZN is $5.49B
What is the all time high annual cash & cash equivalents for AstraZeneca PLC?
AstraZeneca PLC all-time high annual cash & cash equivalents is $10.70B
What is AstraZeneca PLC annual cash & cash equivalents year-on-year change?
Over the past year, AZN annual cash & cash equivalents has changed by -$352.00M (-6.03%)
What is AstraZeneca PLC quarterly cash & cash equivalents?
The current quarterly cash & cash equivalents of AZN is $7.11B
What is the all time high quarterly cash & cash equivalents for AstraZeneca PLC?
AstraZeneca PLC all-time high quarterly cash & cash equivalents is $15.63B
What is AstraZeneca PLC quarterly cash & cash equivalents year-on-year change?
Over the past year, AZN quarterly cash & cash equivalents has changed by +$32.00M (+0.45%)